Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32065
Title: Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.
Austin Authors: Cliff, Edward R Scheffer;Reynolds, Gemma;Popat, Rakesh;Teh, Benjamin W;Kesselheim, Aaron S;Mohyuddin, Ghulam Rehman
Affiliation: Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham Women's Hospital, Harvard Medical School, Boston, MA
National Center for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Infectious Diseases
Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, United Kingdom
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Issue Date: 1-Apr-2023
Date: 2023
Publication information: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2023; 41(10)
URI: https://ahro.austin.org.au/austinjspui/handle/1/32065
DOI: 10.1200/JCO.22.02197
ORCID: 0000-0001-5977-907X
0000-0001-6553-4618
0000-0003-0213-5470
0000-0001-6464-783X
Journal: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Start page: JCO2202197
PubMed URL: 36716411
ISSN: 1527-7755
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Apr 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.